Overview

Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma

Status:
NOT_YET_RECRUITING
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma
Phase:
PHASE3
Details
Lead Sponsor:
mAbxience Research S.L.